Fig. 3: Synergistic inhibition of SARS-CoV-2 replication through combination of MB-905 and repurposed viral exonuclease inhibitors. | Nature Communications

Fig. 3: Synergistic inhibition of SARS-CoV-2 replication through combination of MB-905 and repurposed viral exonuclease inhibitors.

From: Preclinical development of kinetin as a safe error-prone SARS-CoV-2 antiviral able to attenuate virus-induced inflammation

Fig. 3

Infected calu-3 cells were treated with the indicated concentrations of MBs with raltegravir (RTG) (a) or dolutegravir (DTG) (b), followed by titration in Vero cells. Ordinary one-way ANOVA test was used to compare Nil vs the other groups, P = 0.0052 represents the minimum statistical significance, between Nil and sofosbuvir. For specific comparisons between two groups, treated with a nucleic acid component analog vs its combination with RTG (a) or DTG (b) one-tailed Student’s T test was performed. Infected calu-3 cells were treated with the full curve of MB-905 or dolutegravir, followed by titration in Vero cells and analysis for synergy using SinergyFinder2.0 (https://synergyfinder.fimm.fi/) (c). Scores above 10 indicate synergy. The data represent the means ± SEMs of three independent experiments.

Back to article page